Literature DB >> 27707922

Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.

Yu Okubo1,2, Hiroaki Uchida3, Aika Wakata2, Takuma Suzuki1,2, Tomoko Shibata1,2, Hitomi Ikeda1,2, Miki Yamaguchi4, Justus B Cohen5, Joseph C Glorioso5, Mitsuo Tagaya2, Hirofumi Hamada2,4, Hideaki Tahara1.   

Abstract

Membrane fusion, which is the key process for both initial cell entry and subsequent lateral spread of herpes simplex virus (HSV), requires the four envelope glycoproteins gB, gD, gH, and gL. Syncytial mutations, predominantly mapped to the gB and gK genes, confer hyperfusogenicity on HSV and cause multinucleated giant cells, termed syncytia. Here we asked whether interaction of gD with a cognate entry receptor remains indispensable for initiating membrane fusion of syncytial strains. To address this question, we took advantage of mutant viruses whose viral entry into cells relies on the uniquely specific interaction of an engineered gD with epidermal growth factor receptor (EGFR). We introduced selected syncytial mutations into gB and/or gK of the EGFR-retargeted HSV and found that these mutations, especially when combined, enabled formation of extensive syncytia by human cancer cell lines that express the target receptor; these syncytia were substantially larger than the plaques formed by the parental retargeted HSV strain. We assessed the EGFR dependence of entry and spread separately by using direct entry and infectious center assays, respectively, and we found that the syncytial mutations did not override the receptor specificity of the retargeted viruses at either stage. We discuss the implications of these results for the development of more effective targeted oncolytic HSV vectors. IMPORTANCE: Herpes simplex virus (HSV) is investigated not only as a human pathogen but also as a promising agent for oncolytic virotherapy. We previously showed that both the initial entry and subsequent lateral spread of HSV can be retargeted to cells expressing tumor-associated antigens by single-chain antibodies fused to a receptor-binding-deficient envelope glycoprotein D (gD). Here we introduced syncytial mutations into the gB and/or gK gene of gD-retargeted HSVs to determine whether viral tropism remained dependent on the interaction of gD with the target receptor. Entry and spread profiles of the recombinant viruses indicated that gD retargeting does not abolish the hyperfusogenic activity of syncytial mutations and that these mutations do not eliminate the dependence of HSV entry and spread on a specific gD-receptor interaction. These observations suggest that syncytial mutations may be valuable for increasing the tumor-specific spreading of retargeted oncolytic HSV vectors.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27707922      PMCID: PMC5126368          DOI: 10.1128/JVI.01456-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Phenotypic and genotypic characterization of locus Syn 5 in herpes simplex virus 1.

Authors:  M Tognon; R Guandalini; M G Romanelli; R Manservigi; B Trevisani
Journal:  Virus Res       Date:  1991-03       Impact factor: 3.303

2.  Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family.

Authors:  R I Montgomery; M S Warner; B J Lum; P G Spear
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

3.  Development of a sensitive screening method for selecting monoclonal antibodies to be internalized by cells.

Authors:  Miki Yamaguchi; Yukari Nishii; Kiminori Nakamura; Haruka Aoki; Sachie Hirai; Hiroaki Uchida; Yuji Sakuma; Hirofumi Hamada
Journal:  Biochem Biophys Res Commun       Date:  2014-11-01       Impact factor: 3.575

4.  The single base pair substitution responsible for the Syn phenotype of herpes simplex virus type 1, strain MP.

Authors:  K L Pogue-Geile; P G Spear
Journal:  Virology       Date:  1987-03       Impact factor: 3.616

5.  The herpes simplex virus type 1 UL20 protein and the amino terminus of glycoprotein K (gK) physically interact with gB.

Authors:  Vladimir N Chouljenko; Arun V Iyer; Sona Chowdhury; Joohyun Kim; Konstantin G Kousoulas
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

6.  Syncytial mutations in the herpes simplex virus type 1 gK (UL53) gene occur in two distinct domains.

Authors:  K E Dolter; R Ramaswamy; T C Holland
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection.

Authors:  Hiroaki Uchida; Janet Chan; William F Goins; Paola Grandi; Izumi Kumagai; Justus B Cohen; Joseph C Glorioso
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

8.  A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry.

Authors:  D Shukla; J Liu; P Blaiklock; N W Shworak; X Bai; J D Esko; G H Cohen; R J Eisenberg; R D Rosenberg; P G Spear
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

9.  Truncation of the carboxy-terminal 28 amino acids of glycoprotein B specified by herpes simplex virus type 1 mutant amb1511-7 causes extensive cell fusion.

Authors:  A Baghian; L Huang; S Newman; S Jayachandra; K G Kousoulas
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.

Authors:  Anna Israyelyan; Vladimir N Chouljenko; Abolghasem Baghian; Andrew T David; Michael T Kearney; Konstantin G Kousoulas
Journal:  Virol J       Date:  2008-06-02       Impact factor: 4.099

View more
  1 in total

Review 1.  Cell Fusion and Syncytium Formation in Betaherpesvirus Infection.

Authors:  Jiajia Tang; Giada Frascaroli; Xuan Zhou; Jan Knickmann; Wolfram Brune
Journal:  Viruses       Date:  2021-09-30       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.